29 September 2021

24 September2021 The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, and is updated regularly as new evidence emerges. This sixth version of the WHO guideline now contains nine recommendations, including two new recommendations regarding the use of a combination of neutralizing monoclonal antibodies, casirivimab and imdevimab. No further updates to the previous existing recommendations were made in this latest versio

BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379 Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RECOVERY and REMAP-CAP randomised controlled trials triggered this guideline update, resulting in a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19. Prior recommendations: (a) A recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (b) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (c) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (d) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (e) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (f) a conditional recommendation against remdesivir in hospitalised patients with covid-19

Orientations provisoires 19 juillet 2021

interim guidance, 19 July 2021 (arabic version)

В целом считается, что люди, страдающие астмой (ЛСА), подвергаются повышенному риску при респираторных инфекциях, что ежегодно подтверждается во время вспышек гриппа. Уже в начале пандемии COVID-19 широкое распространение получило мнение о том, что ЛСА подвергаются более высокому риску в связи с COVID-19. Однако, по мере накопления данных за 2020 г., связь между астмой и COVID-19 стала менее очевидной

Note d’information scientifique, 17 juin 2021

The purpose of this document is to stop to irrational use/ over prescription of this reserve/ experimental/ emergency use authorisation drug Remdesivir. For this reason, Joint Monitoring Group under Chairmanship of DGHS took into consideration findings of the following studies to issue this advisory